MIAMI, July 16, 2019 (GLOBE NEWSWIRE) -- Alz1, a brand of Igea Pharma focused on reinventing proactive healthcare in Alzheimer’s disease, today announced the launch of Alz1, the first solution designed to detect and reduce high free copper levels in the bloodstream — a risk factor associated with Alzheimer's disease — through a first-of-its-kind in-home blood test and dietary supplement for those with elevated free copper levels.1
“The digital revolution has sparked a shift in the way consumers think about and access healthcare,” said Diego Mortillaro, CEO at Igea Pharma. “Rather than waiting and reacting to symptoms of disease, consumers are enhancing their focus on monitoring and reduction of risk factors to improve their health and wellness — and they increasingly want the opportunity to do so from the comfort of their own homes. Our revolutionary Alz1 solution empowers consumers with the information they need to take steps now that can reduce a major risk factor for a disease nearly 6 million Americans are living with today — Alzheimer’s disease.”
The Alz1 Kit, available exclusively online, is a revolutionary and easy-to-use blood collection kit designed to measure free copper, a modifiable risk factor that can contribute to the onset and progression of Alzheimer’s disease. Through the identification of free copper, the test empowers users to take proactive control — like lifestyle and dietary changes — of their health and well-being. With no doctor’s appointment, prescription or need to bill insurance, Alz1 ensures this area of strategic proactive healthcare is easier than ever.
When the test results show high free copper levels, users have the option to choose the Alz1 Tab, a natural dietary supplement designed to reduce and control heavy metal contents in the bloodstream, including free copper. Containing glutathione and oleuropein, among other ingredients, the Alz1 Tab could be useful in protecting against neurodegeneration.
Following a seamless order experience, the Alz1 Kit is delivered right to a customer’s door. From there, customers simply register the kit and follow the instructions to collect the blood sample. Using a pre-paid envelope, customers send the sample back to Alz1’s CLIA-certified and CAP-accredited laboratory, where it will be quickly analyzed. Test results will be shared exclusively with users through Alz1’s secure online platform.
“In recent years, several of the most promising programs to develop drugs for the treatment of Alzheimer’s disease failed,” said Mortillaro. “Compounding the issue, the Alzheimer’s Association revealed that the number of Americans who have Alzheimer’s is expected to increase to 14 million (from 5.8 million today) by 2050. Consequently, proactive healthcare habits are important to help protect yourself from the most common cause of dementia. Our mission is to find better, more convenient ways to help consumers have a positive impact on proven risk factors of Alzheimer’s.”
For more information about the company, the Alz1 Kit, the Alz1 Tab or why detecting free copper in the bloodstream is important, please visit https://alz1.com/.
About Alz1
Alz1, a Miami-based brand of Igea Pharma, leverages the deep scientific knowledge of Igea Pharma’s scientific advisory board to reinvent proactive healthcare in Alzheimer’s disease by capitalizing on digital economy opportunities and recent healthcare industry trends. The simple and convenient Alz1 Kit is an at-home blood test designed to detect free copper in the bloodstream — high levels of which indicate one of the risk factors for Alzheimer’s disease. The Alz1 Tab, a natural dietary supplement, helps decrease heavy metal contents, including free copper, in the bloodstream. For information, visit https://alz1.com/.
###
Certain information set forth in this document may contain “forward-looking information” under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein may constitute forward-looking statements. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
1 These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.